Pillar Pacific Capital Management LLC held its position in Pfizer, Inc. (NYSE:PFE) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,359 shares of the biopharmaceutical company’s stock at the end of the first quarter. Pillar Pacific Capital Management LLC’s holdings in Pfizer were worth $525,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of PFE. Searle & CO. increased its stake in shares of Pfizer by 92.7% in the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after buying an additional 38,500 shares during the period. Nwam LLC increased its stake in shares of Pfizer by 5.3% in the first quarter. Nwam LLC now owns 53,786 shares of the biopharmaceutical company’s stock worth $1,840,000 after buying an additional 2,699 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Pfizer by 1.0% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 17,376,931 shares of the biopharmaceutical company’s stock worth $594,465,000 after buying an additional 169,073 shares during the period. Eqis Capital Management Inc. increased its stake in shares of Pfizer by 11.2% in the first quarter. Eqis Capital Management Inc. now owns 48,469 shares of the biopharmaceutical company’s stock worth $1,658,000 after buying an additional 4,870 shares during the period. Finally, Tyers Asset Management LLC increased its stake in shares of Pfizer by 41.9% in the first quarter. Tyers Asset Management LLC now owns 184,668 shares of the biopharmaceutical company’s stock worth $6,318,000 after buying an additional 54,494 shares during the period. Hedge funds and other institutional investors own 69.09% of the company’s stock.

Pfizer, Inc. (PFE) traded down 0.27% during mid-day trading on Tuesday, reaching $33.38. 2,862,558 shares of the company’s stock traded hands. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.18. The firm’s 50-day moving average price is $33.25 and its 200 day moving average price is $33.42. The stock has a market capitalization of $198.52 billion, a PE ratio of 24.42 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company’s revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.64 EPS. Equities research analysts predict that Pfizer, Inc. will post $2.56 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.82%. Pfizer’s dividend payout ratio is currently 94.12%.

ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (PFE) Stake Held by Pillar Pacific Capital Management LLC” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/29/pfizer-inc-pfe-stake-held-by-pillar-pacific-capital-management-llc.html.

PFE has been the subject of a number of recent research reports. Sanford C. Bernstein reiterated a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Barclays PLC reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Citigroup Inc. downgraded shares of Pfizer from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Morgan Stanley restated a “neutral” rating and issued a $35.00 target price (down from $38.00) on shares of Pfizer in a report on Monday, June 12th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $37.61.

In related news, insider Laurie J. Olson sold 8,064 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares in the company, valued at approximately $2,436,346.20. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 120,014 shares of company stock valued at $4,062,493. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.